Literature DB >> 21217678

Catapulting clopidogrel pharmacogenomics forward.

Eric J Topol, Nicholas J Schork.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21217678     DOI： 10.1038/nm0111-40

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

1.  The case for routine genotyping in dual-antiplatelet therapy.

Authors:  Samir B Damani; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2010-05-13       Impact factor: 24.094

2.  Variability in platelet responsiveness to clopidogrel among 544 individuals.

Authors:  Victor L Serebruany; Steven R Steinhubl; Peter B Berger; Alex I Malinin; Deepak L Bhatt; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

3.  Stent thrombosis in randomized clinical trials of drug-eluting stents.

Authors:  Laura Mauri; Wen-hua Hsieh; Joseph M Massaro; Kalon K L Ho; Ralph D'Agostino; Donald E Cutlip
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

4.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

5.  Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.

Authors:  Jean-Sébastien Hulot; Jean-Philippe Collet; Johanne Silvain; Ana Pena; Anne Bellemain-Appaix; Olivier Barthélémy; Guillaume Cayla; Farzin Beygui; Gilles Montalescot
Journal:  J Am Coll Cardiol       Date:  2010-07-06       Impact factor: 24.094

6.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Authors:  Jean-Sébastien Hulot; Alessandra Bura; Eric Villard; Michel Azizi; Véronique Remones; Catherine Goyenvalle; Martine Aiach; Philippe Lechat; Pascale Gaussem
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

7.  Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Authors:  Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

8.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

9.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

10.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245
View more
  5 in total

1.  Extracellular ADP facilitates monocyte recruitment in bacterial infection via ERK signaling.

Authors:  Xiaoyu Zhang; Juliang Qin; Junyan Zou; Zhangsheng Lv; Binghe Tan; Jueping Shi; Yihan Zhao; Hua Ren; Mingyao Liu; Min Qian; Bing Du
Journal:  Cell Mol Immunol       Date:  2016-11-21       Impact factor: 11.530

Review 2.  Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1.

Authors:  Thomas M Polasek; Matthew P Doogue; John O Miners
Journal:  Ther Adv Drug Saf       Date:  2011-12

3.  Transanal hemorrhoidal dearterialization (THD): a safe procedure for the anticoagulated patient?

Authors:  S Atallah; G K Maharaja; B Martin-Perez; J P Burke; M R Albert; S W Larach
Journal:  Tech Coloproctol       Date:  2016-05-12       Impact factor: 3.781

4.  A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance.

Authors:  Lichen Zhang; Xiaowei Ma; Guoling You; Xiaoqing Zhang; Qihua Fu
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

5.  A systematic review and meta-analysis of traumatic intracranial hemorrhage in patients taking prehospital antiplatelet therapy: Is there a role for platelet transfusions?

Authors:  Jurgis Alvikas; Sara P Myers; Charles B Wessel; David O Okonkwo; Bellal Joseph; Carlos Pelaez; Cody Doberstein; Andrew R Guillotte; Matthew R Rosengart; Matthew D Neal
Journal:  J Trauma Acute Care Surg       Date:  2020-06       Impact factor: 3.697
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.